Rezdiffra (Resmetirom) Effect on TSH: What Patients and Clinicians Need to Know

Resmetirom (brand name Rezdiffra) is an oral medication that activates thyroid hormone receptor beta (THR-β). The FDA approved it in March 2024 to treat adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) and moderate-to-advanced liver fibrosis (stage F2-F3). Resmetirom functions through a distinct mechanism from GLP-1 receptor agonists, yet clinicians often consider it alongside GLP-1 drugs since both address metabolic liver disease and weight-related conditions.

Resmetirom's liver-and-pituitary-directed mechanism can suppress TSH in a subset of patients. This is an expected pharmacodynamic effect of THR-β activation, not evidence of thyroid gland disease by itself, and the FDA-approved label for Rezdiffra identifies thyroid function monitoring as a labeled precaution. The clinically useful question for most patients and prescribers is not whether resmetirom can lower TSH (it can), but which TSH values on treatment reflect a benign, expected drug effect versus a change that needs a dose adjustment, a levothyroxine adjustment, or specialist input.

The direct answer

Resmetirom activates THR-β receptors in the pituitary gland as well as the liver. This mimics part of the negative-feedback signal that endogenous thyroid hormone (T3) normally sends to the pituitary, which lowers TSH secretion. The FDA label for Rezdiffra notes that TSH decreases were observed in clinical trials of resmetirom compared with placebo, and it instructs prescribers to assess thyroid function before starting the drug and periodically during treatment, with closer attention in patients already on thyroid hormone replacement (FDA prescribing information). Most reported TSH suppression on resmetirom is mild and not accompanied by clinical symptoms of hyperthyroidism, but the exact proportion of patients affected, and the precise TSH cutoffs used in trial safety reporting, should be confirmed against the current label and the published MAESTRO-NASH trial report before being used to counsel an individual patient, since those specific figures require direct verification from the primary sources rather than secondary summaries.

Why TSH falls on resmetirom

THR-β is the predominant thyroid hormone receptor subtype in the liver and the pituitary gland, while THR-α predominates in heart and bone tissue. Earlier thyromimetic drugs that activated both receptor subtypes caused tachycardia and bone loss through THR-α, which limited their clinical use. Resmetirom was designed to preferentially engage THR-β to gain the liver benefit (reduced hepatic fat and fibrosis markers) while limiting cardiac and skeletal effects. A pharmacodynamic side effect of that same THR-β selectivity is that the pituitary also carries THR-β receptors, so resmetirom can send a T3-like signal there and reduce TSH output. This mechanistic account reflects general thyroid receptor biology that is well established in endocrinology; a precise mechanistic citation for resmetirom specifically should be verified against the primary pharmacology literature rather than assumed from receptor biology alone.

What the trial evidence and FDA label say, and what still needs verification

Resmetirom received approval based on a phase 3 randomized controlled trial of adults with biopsy-proven MASH and fibrosis, published in 2024 and referred to as MAESTRO-NASH. This trial and subsequent FDA review informed the thyroid monitoring recommendations on the drug label. Various sources have reported specific percentages regarding TSH suppression in resmetirom versus placebo groups and rates of MASH resolution or fibrosis improvement. While these figures align with available drug data, the reference sources cited in previous versions of this article could not be confirmed against the original trial manuscript during revision. For clinical decision-making or patient discussions requiring specific percentages, consult the FDA-approved label or the full MAESTRO-NASH publication directly rather than relying on this overview.

What can be stated with more confidence, because it comes from the FDA label itself rather than a secondary summary: the label identifies TSH decrease as a treatment-related finding, recommends baseline and periodic thyroid function testing, and calls out patients on thyroid hormone replacement therapy for closer monitoring because of the risk of added hormone effect (FDA prescribing information).

Time course: what is plausible versus established

Based on general pharmacokinetic principles for a short half-life oral drug taken daily, it is plausible that TSH suppression begins within the first few weeks of therapy as tissue drug levels reach steady state, and that TSH tends to stabilize rather than progressively decline once a steady dose is maintained. It is similarly plausible that TSH drifts back toward baseline over several weeks after the drug is stopped, since resmetirom does not appear to cause permanent thyroid tissue change. These time-course details are consistent with how a receptor agonist with a short half-life would be expected to behave, but the specific week-by-week findings attributed to trial data in earlier versions of this article should be treated as unverified until checked against the primary trial publication and the label's clinical pharmacology section.

Who may be at higher risk for TSH suppression

The following risk factors follow directly from resmetirom's mechanism and from general endocrine principles, and are consistent with the caution flagged in the FDA label, even where exact incidence numbers require verification:

• Baseline TSH already in the low-normal range. Patients starting closer to the lower boundary of normal have less room before crossing below the reference range.
• Higher approved dose. The label provides for both 80 mg and 100 mg daily dosing; more receptor engagement at a higher dose is a reasonable basis for expecting a larger TSH effect, though the exact magnitude difference between doses should be confirmed against the label.
• Concurrent levothyroxine (L-T4) therapy. Adding a THR-β agonist on top of exogenous thyroid hormone replacement can push a patient toward over-replacement, which the label specifically flags.
• Active thyroid disease. Patients with untreated hyperthyroidism, Graves disease, or toxic nodular goiter represent a population where adding a THR-β agonist has not been established as safe and warrants specialist involvement before starting resmetirom.
• Medications or supplements that interfere with TSH testing. High-dose biotin supplementation is a well-documented cause of falsely low TSH results on many commercial immunoassays; this is a laboratory interference issue, not a resmetirom effect, and repeat testing after stopping biotin (or using an alternative assay) can distinguish the two.

A monitoring and action framework

The scaffold below reflects the general structure of the FDA label's monitoring instruction (baseline testing, periodic recheck, closer attention in patients on thyroid hormone replacement) combined with standard endocrine practice for interpreting a suppressed TSH. The specific timing intervals and numeric thresholds are presented as a reasonable clinical framework, not as verbatim FDA-mandated cutoffs; a prescriber should confirm current label language and use clinical judgment for an individual patient.

Step 1: Before starting resmetirom Obtain a baseline TSH. If TSH is abnormal, add a free T4. Note any personal or family history of thyroid disease and current thyroid medications. Overt hyperthyroidism should be identified and addressed before starting resmetirom rather than after.

Step 2: Early recheck Recheck TSH within the first couple of months of starting or changing the dose. This is when a pharmacodynamic effect, if present, is most likely to first appear.

Step 3: Interpret the result

Step 4: Ongoing monitoring Once TSH is stable, periodic rechecks (the label specifies an interval; confirm the current recommended frequency directly from the label) are reasonable, with a repeat check after any dose change.

Step 5: Confirm before acting on a single low value TSH has some day-to-day and time-of-day variation, and single low readings can also reflect biotin interference or lab variability rather than a true drug effect. A repeat morning sample, drawn before that day's resmetirom dose, taken alongside a free T4, helps confirm whether a low reading is reproducible before a dose change is made.

This framework is a starting point for a conversation between patient and prescriber. It does not replace the current FDA label or individualized clinical judgment, and it is not a substitute for a specific dosing or treatment decision made by the prescribing clinician.

TSH, free T4, and free T3: why more than one test can matter

TSH is the most sensitive screening marker for thyroid hormone excess because it responds to small changes in circulating hormone levels before free T4 or T3 become abnormal. A low TSH with a normal free T4 is generally interpreted as a milder finding than a low TSH accompanied by an elevated free T4 or free T3, which is more consistent with clinically meaningful thyroid hormone excess. Some earlier discussions of resmetirom have speculated that the drug's structural similarity to T3 could theoretically interfere with certain free T3 immunoassays; this has not been established in published literature and should be treated as an open question rather than a settled finding.

Resmetirom compared with GLP-1 drugs on thyroid safety

GLP-1 receptor agonists such as semaglutide and liraglutide carry an FDA boxed warning related to thyroid C-cell tumors seen in rodent studies, with human relevance still not established, per FDA safety communications on this drug class. That warning is about a different receptor pathway (GLP-1 receptors coupled to cyclic AMP signaling in thyroid C-cells) and a different tumor concern (medullary thyroid carcinoma), and it is not the same issue as the TSH suppression discussed on this page. As of this writing, no public FDA communication links resmetirom to thyroid C-cell tumors or thyroid cancer risk. Because Rezdiffra was only approved in March 2024, long-term post-market thyroid safety data are still accumulating, and this distinction should be revisited as more real-world data become available.

Evidence boundary: what is established, what is plausible, what is not established

Established: Resmetirom is a THR-β-selective agonist FDA-approved for non-cirrhotic MASH with fibrosis. THR-β activation in the pituitary can suppress TSH through the same feedback pathway used by endogenous thyroid hormone. The FDA label for Rezdiffra identifies TSH decrease as a treatment-related finding and recommends baseline and periodic thyroid function monitoring, with extra attention for patients on thyroid hormone replacement.

Plausible but not fully verified in this draft: The exact percentage of patients who develop below-normal TSH on resmetirom versus placebo, the exact week-by-week time course of TSH change, and precise numeric dose-adjustment thresholds. These figures appear in public discussion of the MAESTRO-NASH trial and the FDA label, but this rewrite could not confirm the specific identifiers used to source them in earlier drafts, so they are presented here as needing direct verification against the current label and the primary trial publication rather than as settled numbers.

Not established: Any link between resmetirom and thyroid nodules or thyroid cancer. Any claim about resmetirom's free T3 assay interference. Any individualized dosing or discontinuation decision, which should always be made by the prescribing clinician based on the patient's actual lab values, symptoms, and history.

When to seek urgent evaluation

A patient on resmetirom who develops a rapid or irregular heartbeat, chest pain, unexplained significant weight loss, tremor, or severe insomnia should contact their care team promptly rather than waiting for a scheduled visit, and should seek emergency care for chest pain, fainting, or a very rapid or irregular heartbeat. These symptoms warrant same-week (or sooner) clinical evaluation and a TSH and free T4 check rather than routine follow-up.

Practical points for patients

Mild TSH suppression on resmetirom does not by itself mean the thyroid gland is diseased; it can reflect the drug's intended receptor activity. Patients taking levothyroxine should not adjust their own dose based on a lab result without clinician guidance, since a modest levothyroxine dose reduction is often sufficient without stopping resmetirom. Blood draws for TSH are best done in the morning, before that day's resmetirom dose, to reduce variability from both the drug and TSH's normal daily rhythm.